ReviewJournal of gynecologic oncology2014
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.
Review in Journal of gynecologic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- RSPO1-LGR4 axis drives cervical cancer progression via activation of the EGFR/Src/ERK/AKT signaling pathway.Neoplasia (New York, N.Y.) · 2026Article
- Construction and validation of a novel prognostic risk model in cervical cancer: integrating lactylation-related genes linked to radiotherapy‑associated transcriptional changes.Discover oncology · 2026Article
- Inhibitory Effect of TrxR Inhibitor Ag (Ⅰ) Schiff Base Complex Against Cervical Cancer Via ROS-mediated ASK1/MAPK Signaling and Autophagy.Biological trace element research · 2026Article
- Cervical cancer in the modern era: cutting-edge strategies for diagnosis and treatment.Japanese journal of radiology · 2026Review
- Review
- Cancer Stem Cells and Their Possible Implications in Cervical Cancer: A Short Review.International journal of molecular sciences · 2022Review
- PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.Molecules (Basel, Switzerland) · 2021Review
- Angiogenic Potential in Biological Hydrogels.Biomedicines · 2020Review
- The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature.Current treatment options in oncology · 2020Review
- Article
- The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.Frontiers in immunology · 2020Review
- Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas.Oncotarget · 2018Article
- Targeted therapy in cervical cancer.ESMO open · 2018Article
- Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation.Oncotarget · 2017Article
- Evaluation and clinical significance of cyclin-dependent kinase5 expression in cervical lesions: a clinical research study in Guangxi, China.European journal of medical research · 2016Article
- Novel 1, 3-N, O-Spiroheterocyclic compounds inhibit heparanase activity and enhance nedaplatin-induced cytotoxicity in cervical cancer cells.Oncotarget · 2016Article
- Observational
- Review
- Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression.Cancer cell international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global burden of advanced stage cervical cancer remains significant, particular in resource poor countries where effective screening programs are absent. Unfortunately, a proportion of patients will be diagnosed with advanced stage disease, and may suffer from persistent or recurrent disease despite treatment with combination chemotherapy and radiation. Patients with recurrent disease have a poor salvage rate, with an expected 5-year survival of less than 10%. Recently, significant gains have been made in the antiangiogenic arena; nonetheless the need to develop effective alternate targeted strategies is implicit. As such, a review of molecular targeted therapy in the treatment of this disease is warranted. In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, represents an exciting arena yet to be fully explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.